A recently developed diagnostic tool that combines plasma protein biomarkers, single nucleotide polymorphisms (SNPs), and clinical variables, showed a better performance [area under the curve (AUC) = 0.74] to detect high-risk prostate cancer compared with PSA alone (AUC = 0.56), and avoid 44% of benign biopsies [4]. This evidence concerns the gene KLK3 and prostate cancer.